eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 20
 
Share:
Send email
Share:
Original paper

Incidence and predictors of device-related thrombus after left atrial appendage closure with Watchman device

Jakub Maksym
1
,
Piotr Scisło
1
,
Agnieszka Kapłon-Cieślicka
1
,
Zenon Huczek
1
,
Michał Marchel
1
,
Janusz Kochman
1
,
Karol Zbroński
1
,
Grzegorz Opolski
1
,
Marcin Grabowski
1
,
Tomasz Mazurek
1

  1. First Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
Adv Interv Cardiol 2024; 20, 2 (76): 164–171
DOI: https://doi.org/10.5114/aic.2024.140315
Online publish date: 2024/06/05
Article file
- Incidence and predictors (1).pdf  [0.17 MB]
Get citation
 
 
1. Li SY, Wang J, Hui X, et al. Meta-analysis of postoperative antithrombotic therapy after left atrial appendage occlusion. J Int Med Res 2020; 48: 300060520966478.
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498.
3. Holmes DR Jr, Alkhouli M, Reddy V. Left atrial appendage occlusion for the unmet clinical needs of stroke prevention in nonvalvular atrial fibrillation. Mayo Clin Proc 2019; 94: 864-74.
4. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014; 312: 1988-98.
5. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014; 64: 1-12.
6. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016; 37: 2465-74.
7. Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016; 11: 1170-9.
8. López Mínguez JR, Asensio JM, Costa M, et al. Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. Heart 2015; 101: 877-83.
9. Dukkipati SR, Kar S, Holmes DR, et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation 2018; 138: 874-85.
10. Lempereur M, Aminian A, Freixa X, et al. Device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv 2017; 90: E111-21.
11. Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol 2018; 71: 1528-36.
12. Maksym J, Kapłon-Cieślicka A, Scisło P, et al. Safety and efficacy of percutaneous atrial appendage closure followed by antiplatelet therapy in a high-risk population: single-center experience with a WATCHMAN device. Adv Interv Cardiol 2023; 19: 262-9.
13. Main ML, Fan D, Reddy VY, et al. Assessment of device-related thrombus and associated clinical outcomes with the WATCHMAN left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF Trial). Am J Cardiol 2016; 117: 1127-34.
14. Maksym J, Grabowski M, Mazurek T. Percutaneous left atrial appendage closure with the Watchman device: a systematic review. Adv Interv Cardiol 2024; 20: 18-29.
15. Plicht B, Konorza TF, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer Cardiac Plug after left atrial appendage occlusion. JACC Cardiovasc Interv 2013; 6: 606-13.
16. Potpara T, Grygier M, Häusler KG, et al. Practical guide on left atrial appendage closure for the non-implanting physician: an international consensus paper. Europace 2024; 26: euae035.
17. Sedaghat A, Nickenig G, Schrickel JW, et al. Incidence, predictors and outcomes of device-related thrombus after left atrial appendage closure with the WATCHMAN device-Insights from the EWOLUTION real world registry. Catheter Cardiovasc Interv 2021; 97: E1019-24.
18. Simard T, Jung RG, Lehenbauer K, et al. Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol 2021; 78: 297-313.
19. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013; 61: 2551-6.
20. Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 2017; 14: 1302-8.
21. Bergmann MW, Ince H, Kische S, et al. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention 2018; 13: 2003-11.
22. Søndergaard L, Wong YH, Reddy VY, et al. Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv 2019; 12: 1055-63.
23. Ketterer U, D’Ancona G, Siegel I, et al. Percutaneous left atrial appendage occlusion: device thrombosis in clopidogrel non-responders. Int J Cardiol 2016; 204: 196-7.
24. Patti G, Sticchi A, Verolino G, et al. Safety and efficacy of single versus dual antiplatelet therapy after left atrial appendage occlusion. Am J Cardiol 2020; 134: 83-90.
25. Korsholm K, Nielsen KM, Jensen JM, et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. EuroIntervention 2017; 12: 2075-82.
26. Lowe BS, Kusunose K, Motoki H, et al. Prognostic significance of left atrial appendage “sludge” in patients with atrial fibrillation: a new transesophageal echocardiographic thromboembolic risk factor. J Am Soc Echocardiogr 2014; 27: 1176-83.
27. Sedaghat A, Vij V, Al-Kassou B, et al. Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ Cardiovasc Interv 2021; 14: e010195.
28. Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011; 57: 831-8.
29. Pracon R, Bangalore S, Dzielinska Z, et al. Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy. Circ Cardiovasc Interv 2018; 11: e005997.
30. Korsholm K, Jensen JM, Nørgaard BL, et al. Detection of device-related thrombosis following left atrial appendage occlusion: a comparison between cardiac computed tomography and transesophageal echocardiography. Circ Cardiovasc Interv 2019; 12: e008112.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.